Exocrine Pancreatic Insufficiency Market 2013
Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep, Pancreaze, Ultresa, Viokase, Pertzye) and Phase III Drugs; Diagnostic Test – Blood Tests, Endoscopic ultra-sonography, MRI, and CT Scanning) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023 report at http://www.transparencymarketresearch.com/exocrine-pancreatic-insufficiency.html
Exocrine pancreatic insufficiency (EPI) is a condition characterized by the deficiency of the exocrine pancreatic enzymes, causing failure to digest food properly. Exocrine pancreatic insufficiency is caused due to damage to pancreas. The common causes of EPI are cystic fibrosis, chronic pancreatitis, and Shwachman-Diamond syndrome. The peculiar symptoms of EPI include frequent diarrhea, weight loss, foul-smelling greasy stools, gas and bloating, and stomach ache. Exocrine pancreatic insufficiency is treatable with pancreatic enzyme replacement therapy, which helps in digestion, improves malabsorption and vitamin deficiencies, and fuels weight gain.
Pancreatic enzyme replacement therapy products contain a defined amount of digestive enzymes such as lipases, proteases, and amylases, which are required by the body to metabolize fats, proteins, and sugar from food. Without these enzymes, patients with EPI are less capable of absorbing vital nutrients from food and can become undernourished. Effective management of EPI includes life-long pancreatic enzyme replacement therapy (PERT), lifestyle modifications, modifications with specialized food supplements such as vitamins and nutrients that do not require pancreatic enzymes for digestion, and transplantation of pancreatic cells.
Factors such as the increasing prevalence of diseases such as cystic fibrosis, chronic pancreatitis and diabetes are contributing to an increase in the prevalence of exocrine pancreatic insufficiency. According to recent data released by the Cystic Fibrosis Foundation, about 30,000 people are living with cystic fibrosis in the U.S. and 70,000 across the globe. Approximately 1,000 new cases of cystic fibrosis are diagnosed each year in the U.S. With such alarming rise in the number of people suffering from cystic fibrosis, the risk of incidence related to the disease also increases. People suffering from cystic fibrosis face breathing complications as mucus clogs their lungs and makes them susceptible to infections. Thick mucus also chokes the pancreas and obstructs the release of digestive enzymes leading to the deficiency of these enzymes. EPI is observed in a considerable proportion among the CF patients, with roughly 50% of children with CF suffering from this condition at birth. In addition, 25% of the population develops EPI within the first six months of life. Furthermore, 15% develop EPI in late childhood. According to recent data released by Aptalis (Allergan), chronic pancreatitis is observed in roughly 0.03% to 0.04% adults in the U.S. Of these, around 30% to 40% are expected to develop EPI over a span of 10 years.
Prevalence of EPI is expected to rise due to increase in the number of people suffering from diabetes. According to data published by the Centers for Disease Control and Prevention in 2014, the prevalence of diabetes in the U.S. has increased from 4.40% in 2000 to 7.18% in 2013. Examinations of people suffering from diabetes have shown greater than normal inflammation and damage to pancreatic tissue, signifying the increase in the risk of exocrine pancreatic insufficiency in people suffering from diabetes. The EPI market is also driven by the opportunities offered by developing countries. With an increasing incidence of diseases in this region, demand for PERT products is expected to grow in the next few years. However, stringent FDA regulations for the approval of PERT products are expected to hamper the growth of this market.
Major players in this market are AbbVie, Inc. (U.S.), Allergan plc (Ireland), Nordmark Arzneimittel GmbH & Co. KG (Germany), Digestive Care, Inc. (U.S.), Cilian AG (Germany), Anthera Pharmaceuticals, Inc. (U.S.), Janssen Pharmaceuticals, Inc. (U.S.), and AzurRx BioPharma, Inc. (U.S.).
Get accurate market forecast and analysis on the Exocrine Pancreatic Insufficiency Market. Request a sample to stay abreast on the key trends impacting this market.
Global exocrine pancreatic insufficiency market has been segmented as follows:
Global Exocrine Pancreatic Insufficiency Market, By Therapeutic
Pancreatic Enzyme Replacement Therapy (PERT) products
Phase III drugs
Global Exocrine Pancreatic Insufficiency Market, By Diagnostic Test
Endoscopic Ultra-sonography (EUS)
Magnetic Resonance Imaging (MRI)
Global Exocrine Pancreatic Insufficiency Market, By Geography
Rest of Europe
Rest of Asia Pacific
Rest of Latin America
Rest of the World
Rest of Rest of the World
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Sudip. S
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Exocrine Pancreatic Insufficiency Market 2013 here
News-ID: 555435 • Views: …
More Releases from Transparency Market Research
Global Autonomous Train Technology Market Forecast 2023-2031 - Market Size, Driv …
The autonomous train technology market is poised for substantial growth, reflecting a paradigm shift in the global transportation landscape. Valued at US$ 1.9 billion in 2022, the market is anticipated to witness a robust CAGR of 6.4%, reaching US$ 3.4 billion by 2031. This surge is attributed to key factors such as increased investments in railway infrastructure and the growing demand for reliable, sustainable, and energy-efficient transport systems. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚
Automotive Braking Component Market Size, Share And Growth Analysis For 2023-203 …
The global automotive braking component industry, valued at US$ 47.9 billion in 2022, is poised for significant growth, with an estimated Compound Annual Growth Rate (CAGR) of 4.0% from 2023 to 2031. Projections suggest that the market will reach US$ 68.3 billion by the end of 2031. This robust expansion is attributed to several key factors, including the surge in automotive production and vehicle ownership, advancements in safety technologies, and
Internet of Things (IoT) in Healthcare Market 2022: Industry Analysis, Size, Sha …
The Integration of Internet of Things (Iot) has emerged as a transformative force, catalyzing unprecedented advancements in patient care, operational efficiency, and overall healthcare outcomes. According to the latest market report, the IoT in Healthcare market was valued at a staggering US$ 91.71 billion in 2021 and is projected to exhibit a remarkable CAGR of 21.8% from 2022 to 2031, ultimately reaching an estimated value of US$ 648.94 billion by
Property Management Software Market Analysis, Size, Share, Growth, Trends, and F …
The Property Management Software Market is emerging as a key player in reshaping the way real estate is managed and optimized. According to recent press releases, the global property management software market was valued at an impressive US$ 14.89 billion in 2021, and projections indicate a robust compound annual growth rate (CAGR) of 8.21% from 2022 to 2031. This momentum is expected to catapult the market to a staggering US$
More Releases for EPI
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Global Epi Wafer Market 2018 - Nichia, EpiWorks, Norstel, OMMIC
Eminent Market, recently published a detailed market research study focused on the "Epi Wafer Market" across the global, regional and country level. The report provides 360° analysis of "Epi Wafer Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Epi Wafer industry, and estimates the future trend of Epi Wafer market on
Epitaxial (Epi) Wafer Market Investment Research Report 2025
Epitaxy is a method used to grow or lay a single crystalline film or layer over a crystalline-based semiconductor surface or substrate. The deposited substance must have a definite acclimatization with regard to the crystal-based semiconductor substrate. Moreover, Chip developers applies either molten or vapor based foundations to produce such epitaxial over layers. An epitaxial wafer is a wafer of semiconducting substrate made by epitaxial growth for application in microelectronics,
Global Epi Wafer Market Report Analysis and Forecast 2017
ReportsWeb.com has announced the addition of the “Global Epi Wafer Market Research Report 2017-2022” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. The Global Epi Wafer Market Professional Survey Report 2017 is a professional and in-depth study on the current state of the Epi Wafer market. Annual estimates and forecasts are provided for the period 2017 through 2022. Also, a
Epi Wafer Market 2017 - GlobalWafers, Nichia, EpiWorks
Apex Research, recently published a detailed market research study focused on the "Epi Wafer Market" across the global, regional and country level. The report provides 360° analysis of "Epi Wafer Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Epi Wafer industry, and estimates the future trend of Epi Wafer market on
Epitaxial (Epi) Wafer Market 2017- ASM International, EpiWorks, Jenoptik
Marketreports.biz, recently published a detailed market research study focused on the "Epitaxial (Epi) Wafer Market" across the global, regional and country level. The report provides 360° analysis of "Epitaxial (Epi) Wafer Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Epitaxial (Epi) Wafer industry, and estimates the future trend of Epitaxial